We appreciate the thoughtful comments from our colleague regarding our study on proliferating CD4+ memory T cells as predictors of response to integrin α4β7–blocking therapy in inflammatory bowel disease (IBD). We welcome the opportunity to further discuss the key aspects raised in this letter to the editor.
We will be happy to hear your thoughts